4results about How to "Reduce systemic toxicity" patented technology

This invention discloses a nystatin microsphere with targeted enhanced antifungal function, its preparation method, and its application. The microsphere uses sodium alginate as a carrier, internally encapsulating the antifungal drug nystatin. The surface is covalently modified with the β-glucan binding domain of the Dectin-1 protein, constructing a smart drug delivery system with fungal targeting function. The microsphere preparation process is simple and reproducible, and can be scalable using an emulsion-ionic crosslinking method combined with protein coupling technology. In vitro characterization shows that the microspheres have uniform particle size and stable dispersion, and Dectin-1 modification significantly enhances their specific binding ability against Candida albicans. This targeted delivery system, while successfully preserving drug activity, significantly improves the antifungal efficiency of nystatin through Dectin-1-mediated targeting, achieving efficacy close to that of free drug, and providing a new strategy for constructing highly efficient and long-acting antifungal agents.

The application relates to a MYH2-FIGN interaction blocking amino acid compound and an application thereof, and relates to the fields of polypeptide drugs and tumor prevention and treatment. The MYH2-FIGN interaction blocking amino acid compound is an amino acid sequence as shown in SEQ ID NO:1 or SEQ ID NO:3 or a polypeptide derivative thereof. The application further discloses a pharmaceutical composition containing the MYH2-FIGN interaction blocking amino acid compound and a pharmaceutically acceptable carrier. The application first designs a polypeptide drug targeting the MYH2-FIGN interaction interface, and compared with traditional small molecules, the polypeptide drug has specificity for MYH2-FIGN interaction inhibition, and through fusion of an iRGD peptide, not only is the polypeptide cell penetration problem solved, but also the polypeptide drug is endowed with tumor targeting, the bioavailability of the drug is improved, and the systemic toxicity is reduced. The polypeptide drug can adopt various drug dosage forms, and the preparation process is simple.

This invention discloses a ZIF-8 nanomedicine delivery system co-loaded with doxorubicin and siTDRKH, its preparation method, and its applications, belonging to the fields of biomedicine and nanomaterials technology. The nanomedicine delivery system uses the zeolite imidazole ester framework material ZIF-8 as a carrier. Its porous structure encapsulates the chemotherapeutic drug doxorubicin within the framework, and small interfering RNA targeting the TDRKH gene is loaded onto the surface through electrostatic adsorption. This structure exhibits high pH responsiveness: it remains stable under normal physiological conditions (pH 7.4), preventing premature drug leakage; upon entering the slightly acidic environment of a tumor (pH 6.5) or a lysosomal environment (pH 5.0), the ZIF-8 framework immediately disintegrates, achieving targeted and synergistic release of the loaded drug.

This invention is a divisional application of application number 202010500967.1. The invention relates to a layered double hydroxide material system, its preparation method, and its application, specifically the application of LDH / EDTA layered double hydroxide materials in the preparation of antitumor drugs. The LDH / EDTA layered double hydroxide material is a zinc-aluminum layered double hydroxide loaded with ethylenediaminetetraacetic acid (EDTA); in the EDTA-loaded zinc-aluminum layered double hydroxide, EDTA is anion-exchange-intercalated into the interlayer space of the zinc-aluminum layered double hydroxide; the surface of the EDTA-loaded zinc-aluminum layered double hydroxide is positively charged.